Anthony Hayes net worth and biography

Anthony Hayes Biography and Net Worth

Anthony C. Hayes is the CEO of AIkido Pharma Inc., a NASDAQ-traded (ticker: AIKI) technology commercialization company. Hayes began his tenure by overseeing AIkido’s transformation from a biotechnology company into a diversified corporate entity, committed to advancing innovation by participating in the development of new technologies across several sectors.

As CEO, Hayes developed and implemented a strategic plan to advance AIkido’s mission and objectives and to significantly promote company growth. He identified and brought about multimillion-dollar M&A acquisitions that resulted in some of the largest transactions in technology patents. Hayes is also involved in all aspects of investor relations, representing AIkido in shareholder meetings, at domestic and international conferences, and in television and print media (such as Bloomberg Television and Forbes).

An attorney and former partner of an Am Law 100 firm, Hayes previously co-founded and was managing member of JaNSOME IP Management LLC, an intellectual property monetization firm. JaNSOME provided consulting and advisory services to individuals and companies on best practices for monetization of the asset class.

President George W. Bush gave Hayes special recognition for creating the Wills for Heroes program, a national 501(c)(3), in response to the September 11 attacks (willsforheroes.com). Other honors include IAM IP Personality of 2013, American Board of Trial Advocates Young Lawyer of the Year and “20 Under 40” in Columbia, South Carolina.

Education: Juris Doctor from Tulane University Law School (1995); Bachelor of Arts in economics from Mary Washington College (1990)

Bar Memberships: District of Columbia; Florida; New York; South Carolina

Publications: “Avoiding the Post-Crisis Crisis: How to Prevent Post-Crisis Donation for Victims from Leading to Litigation” (ICMA Journal, January/February 2008)

What is Anthony Hayes' net worth?

The estimated net worth of Anthony Hayes is at least $839,678.88 as of September 12th, 2022. Mr. Hayes owns 122,224 shares of AIkido Pharma stock worth more than $839,679 as of September 28th. This net worth estimate does not reflect any other assets that Mr. Hayes may own. Additionally, Mr. Hayes receives a salary of $460,000.00 as CEO at AIkido Pharma. Learn More about Anthony Hayes' net worth.

How old is Anthony Hayes?

Mr. Hayes is currently 54 years old. Learn More on Anthony Hayes' age.

What is Anthony Hayes' salary?

As the CEO of AIkido Pharma Inc., Mr. Hayes earned a total compensation package of $460,000.00 in 2021. Mr. Hayes earned a salary of $460,000.00, and no other miscellaneous compensation. Learn More on Anthony Hayes' salary.

How do I contact Anthony Hayes?

The corporate mailing address for Mr. Hayes and other AIkido Pharma executives is ONE ROCKEFELLER PLAZA 11TH FLOOR, NEW YORK NY, 10020. AIkido Pharma can also be reached via phone at (112) 745-1374 and via email at [email protected] Learn More on Anthony Hayes' contact information.

Has Anthony Hayes been buying or selling shares of AIkido Pharma?

During the last ninety days, Anthony Hayes has bought $241,856.64 in AIkido Pharma stock. Most recently, on Monday, September 12th, Anthony Hayes bought 38,208 shares of AIkido Pharma stock. The stock was acquired at an average cost of $6.33 per share, with a total value of $241,856.64. Following the completion of the transaction, the chief executive officer now directly owns 122,224 shares of the company's stock, valued at $773,677.92. Learn More on Anthony Hayes' trading history.

Are insiders buying or selling shares of AIkido Pharma?

During the last twelve months, AIkido Pharma insiders bought shares 4 times. They purchased a total of 88,139 shares worth more than $558,357.09. The most recent insider tranaction occured on September, 16th when Director Kyle Michael Wool bought 3,559 shares worth more than $23,275.86. Insiders at AIkido Pharma own 0.6 % of the company. Learn More about insider trades at AIkido Pharma.

Information on this page was last updated on 9/16/2022.

Anthony Hayes Insider Trading History at AIkido Pharma

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/12/2022Buy38,208$6.33$241,856.64122,224View SEC Filing Icon  
5/3/2021Buy10,000$0.99$9,900.00
4/29/2021Buy10,000$0.99$9,900.0068,430View SEC Filing Icon  
4/22/2021Buy10,000$0.93$9,300.00
11/19/2018Buy10,000$0.88$8,800.0044,183View SEC Filing Icon  
6/7/2017Buy1,000$1.00$1,000.004,214View SEC Filing Icon  
5/30/2017Buy1,000$1.04$1,040.0042,183View SEC Filing Icon  
5/26/2017Buy2,000$0.97$1,940.00119,726View SEC Filing Icon  
5/25/2017Buy2,000$0.96$1,920.003,214View SEC Filing Icon  
6/9/2014Buy2,500$1.69$4,225.00View SEC Filing Icon  
4/11/2014Buy4,000$2.35$9,400.00View SEC Filing Icon  
See Full Table

Anthony Hayes Buying and Selling Activity at AIkido Pharma

This chart shows Anthony Hayes's buying and selling at AIkido Pharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AIkido Pharma Company Overview

AIkido Pharma logo
AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.
Read More

Today's Range

Now: $6.91
Low: $6.67
High: $7.03

50 Day Range

MA: $6.15
Low: $5.60
High: $7.03

2 Week Range

Now: $6.91
Low: $4.30
High: $16.58

Volume

1,331 shs

Average Volume

162,611 shs

Market Capitalization

$36.28 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.33